UNSPSC 51373413: Bromodiphenhydramine/codeine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373413 Bromodiphenhydramine/codeine is a Commodity code nominally designating a specific pharmaceutical product, yet recent state and local procurement activity under this code does not align with that narrow scope. The code has surfaced in two recent opportunities that involve broader pharmaceutical procurement rather than this specific active ingredient: Seminole County, Florida's IFB for naloxone and drug deactivation systems, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products. The actual work being solicited spans multi-product pharmaceutical supply agreements, inventory management, and health-initiative support rather than procurement of bromodiphenhydramine/codeine specifically. Issuing bodies include county health departments (Seminole County) and state cooperative purchasing alliances administering on behalf of multiple participating state and local agencies and facilities.

Activity under this code concentrates in Florida and Minnesota, with the Minnesota opportunity extending to Oregon through cooperative purchasing. The Seminole County solicitation (IFB 60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford and a two-year initial term with one-year renewal option. The MMCAP solicitation (S1070000015802, due March 26, 2026) is broader in scope, requesting manufacturers to supply generic multi-source pharmaceuticals and OTC products across multiple state and local government facilities through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co.), with a two-year initial contract term effective July 1, 2026, and evaluation weighted heavily (75 percent) toward price competitiveness. The code shows limited alignment with its nominal pharmaceutical designation; opportunities tagged under it reflect general pharmaceutical supply and health-initiative procurement rather than this specific active ingredient.